Drug-Eluting Stent vs Drug-Eluting Balloon: Clinical Indications
Drug-eluting stents (DES) should be your default choice for most percutaneous coronary interventions, with drug-coated balloons (DCB) reserved primarily for in-stent restenosis and potentially for small vessel disease where you want to avoid permanent implants.
Primary Indication Framework
When to Use DES (First-Line)
DES are strongly preferred in the following scenarios 1:
- Left main disease - High restenosis risk and clinical consequences make DES superior
- De novo lesions in non-small vessels - DES demonstrates lower target lesion revascularization rates 2
- Diabetes mellitus - Pooled analyses show DES reduces restenosis compared to bare-metal stents
- Long lesions - Higher restenosis risk favors DES
- Multiple lesions - Efficacy considerations outweigh other factors
- Bifurcation lesions - Despite higher thrombosis risk, DES preferred over alternatives
- Saphenous vein grafts - Restenosis prevention is critical
When to Use DCB (Selective Indications)
The strongest evidence for DCB use is in-stent restenosis, though paradoxically, even here DES may be superior. Recent meta-analysis shows that for in-stent restenosis, DES actually outperforms DCB (OR for target lesion revascularization with DCB vs DES: 3.54,95% CI 2.05-6.09) 2. However, a nationwide Swedish registry found DCB superior to plain balloon angioplasty for in-stent restenosis over 5 years 3.
DCB may be considered for:
- Small vessel disease (< 3mm) - No significant difference in target lesion revascularization between DCB and DES in this subset 2, 4
- Patients requiring early surgery - When you cannot guarantee 12 months of dual antiplatelet therapy (DAPT)
- High bleeding risk - DCB allows shorter DAPT duration
- Financial barriers to prolonged DAPT - Cost and compliance issues
Critical Safety Considerations
Absolute Contraindications to DES (Use DCB or Bare-Metal Stent)
- Patient cannot tolerate or comply with 12 months of DAPT
- Anticipated surgery requiring DAPT discontinuation within 12 months
- High bleeding risk that precludes prolonged antiplatelet therapy
- Financial barriers preventing DAPT adherence
- History of non-compliance with medical therapy
Before implanting any DES, you must directly question the patient about their ability to comply with and tolerate prolonged DAPT 5. This is a Class I recommendation - failure to do so represents substandard care.
Important Caveats and Pitfalls
The Paclitaxel Signal
Critical safety concern: The increased cardiac death signal with DCB appears driven specifically by paclitaxel-coated balloons (OR 1.63,95% CI 1.17-2.28), while sirolimus-coated balloons show no such signal 2. When selecting DCB, consider sirolimus-based platforms when available, though this finding requires further validation.
DCB Limitations in De Novo Disease
While DCB shows promise, the most recent comprehensive meta-analysis demonstrates that DCB carries significantly higher risks than DES for de novo lesions overall 2:
- Target lesion revascularization: OR 2.22 (95% CI 1.49-3.33)
- Device-oriented composite endpoint: OR 1.86 (95% CI 1.49-2.31)
- Cardiac death: OR 1.53 (95% CI 1.11-2.10)
Technical Considerations
When you do use DES, optimize deployment with 5:
- High-pressure balloon inflation for adequate apposition
- Consider intravascular ultrasound when deployment adequacy is uncertain
- Meticulous technique to minimize late thrombosis risk
Clinical Presentation Does Not Modify Strategy
Important: Whether the patient presents with STEMI, NSTEMI, or unstable angina does not change the relative effectiveness of DCB versus DES 2. Base your decision on lesion characteristics and patient factors, not acute versus stable presentation.
DAPT Duration Requirements
- DES: Minimum 12 months of DAPT required 1
- Bare-metal stents: 30 days of DAPT
- DCB: Shorter DAPT duration acceptable (specific duration varies by protocol)
The greatest risk for DES thrombosis is early DAPT discontinuation - this is non-negotiable 1.